Wolters Kluwer Reaches Definitive Agreement to Sell Its Pharma-Related Marketing & Publishing Services Business to Springer

11/9/2011, 8:01 AM (Source: GlobeNewswire)
Division Will Focus on High Growth Clinical Markets

Alphen aan den Rijn, the Netherlands (November 9, 2011) - Wolters Kluwer, a
market-leading global information services company focused on professionals,
today announced that it has signed a definitive agreement to sell its pharma-
related Marketing & Publishing Services business to Springer. The announcement
follows an earlier announcement by Wolters Kluwer in July that it planned to
divest its pharma-related assets. The transaction is subject to customary
closing conditions, including regulatory approvals.

"The sale of our pharma-related business is part of our strategy to focus on our
core health markets and accelerate growth by providing innovative solutions to
clinicians globally," said Nancy McKinstry, CEO and Chairman of the Executive
Board of Wolters Kluwer.

The agreement encompasses the Marketing & Publishing Services business unit,
part of the Wolters Kluwer Health & Pharma Solutions division. Marketing &
Publishing Services is a leading global provider of strategic marketing,
publishing, and business intelligence products and services to the
pharmaceutical industry as well as to medical libraries and academic and
research institutions. The sale represents approximately 35% of the company's
pharma-related assets in terms of revenue, with Adis and inScience
Communications as the leading brands, and encompasses approximately 450
employees globally.

"This is an exciting time for our business in terms of opportunities," added Bob
Becker, CEO and President of Wolters Kluwer Health & Pharma Solutions. "We
believe that Springer is the best fit for housing the Marketing & Publishing
Services business going forward and I want to express our great appreciation to
the Marketing & Publishing Services employees and wish them all the best for the

The proceeds from this divestment are expected to be used for general corporate
purposes including the reduction of debt levels in line with the company's
stated objectives and investments in the business.

For more information on Wolters Kluwer Health, visit
www.wolterskluwerhealth.com. For more information on Pharma Solutions, visit

About Wolters Kluwer
Wolters Kluwer is a market-leading global information services company.
Professionals in the areas of legal, business, tax, accounting, finance, audit,
risk, compliance, and healthcare rely on Wolters Kluwer's leading information-
enabled tools and software solutions to manage their business efficiently,
deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer had 2010 annual revenues of €3.6 billion, employs approximately
19,000 people worldwide, and maintains operations across Europe, North America,
Asia Pacific, and Latin America, serving customers globally. Wolters Kluwer is
headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on
Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Visit our website, YouTube, follow @Wolters_Kluwer on Twitter, or look up
Wolters Kluwer on Facebook for more for information about our customers, market
positions, brands, and organization.

Should you wish to change how you receive information from Wolters Kluwer,
please click here.

Forward-looking Statements
This press release contains forward-looking statements. These statements may be
identified by words such as "expect", "should", "could", "will", "shall" and
similar expressions. Wolters Kluwer cautions that such forward-looking
statements are qualified by certain risks and uncertainties that could cause
actual results and events to differ materially from what is contemplated by the
forward-looking statements. Factors which could cause actual results to differ
from these forward-looking statements may include, without limitation, general
economic conditions; conditions in the markets in which Wolters Kluwer is
engaged; behavior of customers, suppliers, and competitors; technological
developments; the implementation and execution of new ICT systems or
outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's
businesses, as well as risks related to mergers, acquisitions, and divestments.
In addition, financial risks such as currency movements, interest rate
fluctuations, liquidity, and credit risks could influence future results. The
foregoing list of factors should not be construed as exhaustive. Wolters Kluwer
disclaims any intention or obligation to publicly update or revise any forward-
looking statements, whether as a result of new information, future events, or

Contact: Caroline Wouters Robert Dekker Jon Teppo
Vice President, Vice President, Vice President,
Corporate Communications Communications Investor Relations
Wolters Kluwer Wolters Kluwer Wolters Kluwer
+ 31 (0)172 641 459 Health & Pharma Solutions + 31 (0)172 641 407
press@wolterskluwer.com  +1 (215) 521 8928 ir@wolterskluwer.com

PDF version of Press Release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Wolters Kluwer NV via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.